Endoscopic Sleeve Gastroplasty in Those With a Body Mass Index of 27-30.
Journal
The American journal of gastroenterology
ISSN: 1572-0241
Titre abrégé: Am J Gastroenterol
Pays: United States
ID NLM: 0421030
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
received:
25
03
2023
accepted:
07
08
2023
medline:
5
10
2023
pubmed:
17
8
2023
entrez:
17
8
2023
Statut:
ppublish
Résumé
Endoscopic sleeve gastroplasty (ESG) is safe and effective in patients with a body mass index (BMI) more than 30, with few cases reported in patients with overweight (BMI 27-30). However, evidence is lacking in the overweight group because the procedure is not currently performed routinely for such patients. In this study, we aim to evaluate the safety and efficacy of ESG in patients with a BMI between 27 and 30 who failed other weight loss modalities and/or had weight-related comorbidities. This was a subgroup analysis of data pertaining to adults with a BMI between 27 and 30 who underwent ESG as a primary weight loss intervention. Data were abstracted from our longitudinal, prospective single-center registry. We analyzed weight loss, comorbidity resolution, adverse events, revisions, and quality of life using the Bariatric Analysis and Reporting Outcome System. Of 3,797 ESG procedures, 656 patients (17%) had a BMI of 27-30. The mean age was 33 ± 9 years and women comprised 94% (n = 616) of the sample. The mean % total weight loss at 6, 12, 24, and 36 months after ESG was 11.0 ± 7.2, 15.5 ± 6.3, 15.1 ± 8.3%, and 13.3 ± 9.9%, respectively. Eight of 22 patients with diabetes (36%) and 9 of 51 patients (18%) with hypertension experienced complete remission. Two patients were hospitalized with bleeding. Twenty-three patients (3.5%) underwent revision to laparoscopic sleeve gastrectomy or repeat ESG. Six more patients underwent suture removal. A total of 214 of 261 patients (82%) rated quality of life after ESG as good or better. ESG seems to be well tolerated, safe, and effective in patients with a BMI of 27-30.
Identifiants
pubmed: 37589499
doi: 10.14309/ajg.0000000000002476
pii: 00000434-202310000-00024
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1807-1811Informations de copyright
Copyright © 2023 by The American College of Gastroenterology.
Références
Sartoretto A, Sui Z, Hill C, et al. Endoscopic sleeve gastroplasty (ESG) is a reproducible and effective endoscopic bariatric therapy suitable for widespread clinical adoption: A large, international multicenter study. Obes Surg 2018;28(7):1812–21.
Lopez-Nava G, Laster J, Negi A, et al. Endoscopic sleeve gastroplasty (ESG) for morbid obesity: How effective is it? Surg Endosc 2022;36(1):352–60.
Sullivan S, Kumar N, Edmundowicz SA, et al. ASGE position statement on endoscopic bariatric therapies in clinical practice. Gastrointest Endosc 2015;82(5):767–72.
Neto MG, Silva LB, de Quadros LG, et al. Brazilian consensus on endoscopic sleeve gastroplasty. Obes Surg 2021;31(1):70–8.
Cheskin LJ, Hill C, Adam A, et al. Endoscopic sleeve gastroplasty versus high-intensity diet and lifestyle therapy: A case-matched study. Gastrointest Endosc 2020;91(2):342–9.e1.
Fayad L, Cheskin LJ, Adam A, et al. Endoscopic sleeve gastroplasty versus intragastric balloon insertion: Efficacy, durability, and safety. Endoscopy 2019;51(6):532–9.
Alqahtani AR, Elahmedi M, Aldarwish A, et al. Endoscopic gastroplasty versus laparoscopic sleeve gastrectomy: A noninferiority propensity score-matched comparative study. Gastrointest Endosc 2022;96(1):44–50.
Hedjoudje A, Abu Dayyeh BK, Cheskin LJ, et al. Efficacy and safety of endoscopic sleeve gastroplasty: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2020;18(5):1043–53.e4.
Singh S, Hourneaux de Moura DT, Khan A, et al. Safety and efficacy of endoscopic sleeve gastroplasty worldwide for treatment of obesity: A systematic review and meta-analysis. Surg Obes Relat Dis 2020;16(2):340–51.
Alqahtani A, Al-Darwish A, Mahmoud AE, et al. Short-term outcomes of endoscopic sleeve gastroplasty in 1000 consecutive patients. Gastrointest Endosc 2019;89(6):1132–8.
Oria HE, Moorehead MK. Updated Bariatric Analysis and Reporting Outcome System (BAROS). Surg Obes Relat Dis 2009;5(1):60–6.
Aldeghaither S, Alnaami M, Aldohayan A, et al. Reliability and validity study of the translated Arabic version of Moorehead-Ardelt Quality of Life Questionnaire II. Saudi Med J 2022;43(3):301–6.
Brethauer SA, Kim J, el Chaar M, et al. Standardized outcomes reporting in metabolic and bariatric surgery. Surg Obes Relat Dis 2015;11(3):489–506.
ASGE/ASMBS Task Force on Endoscopic Bariatric Therapy. A pathway to endoscopic bariatric therapies. Surg Obes Relat Dis 2011;7(6):672–82.
Ginsberg GG, Chand B, Cote GA, et al. A pathway to endoscopic bariatric therapies. Gastrointest Endosc 2011;74(5):943–53.
Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: Five-year experience. Ann Surg 2009;250(2):187–96.
Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA 2022;327(2):138–50.
Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: Differences at 5%, 10%, 15%, and over. Curr Obes Rep 2017;6(2):187–94.
de Miranda Neto AA, de Moura DTH, Ribeiro IB, et al. Efficacy and safety of endoscopic sleeve gastroplasty at mid term in the management of overweight and obese patients: A systematic review and meta-analysis. Obes Surg 2020;30(5):1971–87.
Abu Dayyeh BK, Bazerbachi F, Vargas EJ, et al. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): A prospective, multicentre, randomised trial. Lancet 2022;400(10350):441–51.
Alexandre F, Lapergola A, Vannucci M, et al. Endoscopic management of obesity: Impact of endoscopic sleeve gastroplasty on weight loss and co-morbidities at six months and one year. J Visc Surg 2023;160(2s):S38–46.
Lopez-Nava G, Asokkumar R, Negi A, et al. Re-suturing after primary endoscopic sleeve gastroplasty (ESG) for obesity. Surg Endosc 2021;35(6):2523–30.
Boškoski I, Pontecorvi V, Gallo C, et al. Redo endoscopic sleeve gastroplasty: Technical aspects and short-term outcomes. Therap Adv Gastroenterol 2020;13:1756284819896179.
Alqahtani AR, Elahmedi M, Alqahtani YA, et al. Laparoscopic sleeve gastrectomy after endoscopic sleeve gastroplasty: Technical aspects and short-term outcomes. Obes Surg 2019;29(11):3547–52.
Barrichello S, Hourneaux de Moura DT, Hourneaux de Moura EG, et al. Endoscopic sleeve gastroplasty in the management of overweight and obesity: An international multicenter study. Gastrointest Endosc 2019;90(5):770–80.
Wing RR, Espeland MA, Clark JM, et al. Association of weight loss maintenance and weight regain on 4-year changes in CVD risk factors: The action for health in diabetes (look AHEAD) clinical trial. Diabetes Care 2016;39(8):1345–55.
Badurdeen D, Hoff AC, Hedjoudje A, et al. Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss. Gastrointest Endosc 2021;93(6):1316–24.e1.
Kozłowska-Petriczko K, Pawlak KM, Wojciechowska K, et al. The efficacy comparison of endoscopic bariatric therapies: 6-Month versus 12-month intragastric balloon versus endoscopic sleeve gastroplasty. Obes Surg 2023;33(2):498–505.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387(3):205–16.
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 2022;24(8):1553–64.